(IN BRIEF) GSK announced that the European Commission has approved Nucala (mepolizumab) as an add-on maintenance treatment for adults in the EU with uncontrolled COPD characterised by raised blood eosinophils who are already receiving inhaled triple therapy, making it the … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, Marketing, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged American Thoracic Society, blood eosinophils, COPD, CRSwNP, EGPA, emergency department visits, eosinophilic phenotype, European Commission, European Federation of Allergy and Airways Diseases Patients’ Associations, Exacerbations, GSK, GSK Expands Nucala’s European Indications with Landmark Approval for Uncontrolled COPD, GSK Strengthens Its Respiratory Portfolio as Nucala Receives EU Approval for Add-On COPD Treatment, HES, hospitalisations, IL-5, inhaled triple therapy, Kaivan Khavandi, MATINEE trial, mepolizumab, New England Journal of Medicine, Nucala, Phase III, respiratory medicine, Severe Asthma, Susanna Palkonen, type 2 inflammation
Brentford, United Kingdom, 17-May-2018 — /EuropaWire/ — GlaxoSmithKline plc (GSK) will present extensive data from across its respiratory portfolio, pipeline and early phase research programmes at the American Thoracic Society (ATS) conference in San Diego, USA, 19-23 May 2018. Data presented … Read the full press release
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?